MAPT and osteoporosis: Immunohistochemistry staining revealed that dexamethasone-dependent Tau phosphorylation at Ser422 was also abolished by TRx0237 in CIA mice (Fig. 7n, o), further supporting the identification of p-Tau Ser422 as a therapeutic target in osteoporosis.